Limits...
Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598].

Hsia J, Morse M, Levin V - BMC Musculoskelet Disord (2002)

Bottom Line: Hydroxymethylglutaryl coenzyme A reductase inhibitors increase new bone formation in vitro and in rodents.At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.Among osteopenic women, treatment with simvastatin for 12 weeks did not affect markers of bone formation or resorption.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Medicine, George Washington University, Washington, DC, USA. domjah@gwumc.edu

ABSTRACT

Background: Hydroxymethylglutaryl coenzyme A reductase inhibitors increase new bone formation in vitro and in rodents. Results of epidemiologic analyses evaluating the association between use of these cholesterol-lowering drugs, bone mineral density and fracture have been mixed.

Methods: Women (n = 24) with osteopenia, assessed by broad band ultrasound attenuation, were randomized to simvastatin 20 mg, 40 mg or identical-appearing placebo for 12 weeks. Fasting lipid profiles and biochemical markers of bone formation (bone-specific alkaline phosphatase) and resorption (N-telopeptides and C-terminal propeptide of type 1 collagen) were measured at baseline, 6 and 12 weeks.

Results: Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p < 0.01 vs baseline) and 47% (p < 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively. At baseline, bone marker concentrations were similar in the three treatment groups. At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.

Conclusion: Among osteopenic women, treatment with simvastatin for 12 weeks did not affect markers of bone formation or resorption.

No MeSH data available.


Related in: MedlinePlus

Bone markers in women randomized to simvastatin 40 mg daily. Plasma concentrations of bone ALP, CTX-I and NTX-I at baseline, and after 6 and 12 weeks of simvastatin 40 mg qhs are shown for each woman assigned to that treatment group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC79000&req=5

Figure 1: Bone markers in women randomized to simvastatin 40 mg daily. Plasma concentrations of bone ALP, CTX-I and NTX-I at baseline, and after 6 and 12 weeks of simvastatin 40 mg qhs are shown for each woman assigned to that treatment group.

Mentions: Bone marker concentrations are shown in Table 3. At baseline, levels of bone ALP, NTX-I and CTX-I were similar in the 3 treatment groups. At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups. Plasma concentrations of the three bone markers at baseline, 6 and 12 weeks are shown (Fig. 1) for the 8 women assigned to simvastatin 40 mg/day. Neither upward or downward trend is apparent for any of the three bone markers.


Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598].

Hsia J, Morse M, Levin V - BMC Musculoskelet Disord (2002)

Bone markers in women randomized to simvastatin 40 mg daily. Plasma concentrations of bone ALP, CTX-I and NTX-I at baseline, and after 6 and 12 weeks of simvastatin 40 mg qhs are shown for each woman assigned to that treatment group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC79000&req=5

Figure 1: Bone markers in women randomized to simvastatin 40 mg daily. Plasma concentrations of bone ALP, CTX-I and NTX-I at baseline, and after 6 and 12 weeks of simvastatin 40 mg qhs are shown for each woman assigned to that treatment group.
Mentions: Bone marker concentrations are shown in Table 3. At baseline, levels of bone ALP, NTX-I and CTX-I were similar in the 3 treatment groups. At 6 and 12 weeks, bone marker levels remained similar in the 3 treatment groups. Plasma concentrations of the three bone markers at baseline, 6 and 12 weeks are shown (Fig. 1) for the 8 women assigned to simvastatin 40 mg/day. Neither upward or downward trend is apparent for any of the three bone markers.

Bottom Line: Hydroxymethylglutaryl coenzyme A reductase inhibitors increase new bone formation in vitro and in rodents.At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.Among osteopenic women, treatment with simvastatin for 12 weeks did not affect markers of bone formation or resorption.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Medicine, George Washington University, Washington, DC, USA. domjah@gwumc.edu

ABSTRACT

Background: Hydroxymethylglutaryl coenzyme A reductase inhibitors increase new bone formation in vitro and in rodents. Results of epidemiologic analyses evaluating the association between use of these cholesterol-lowering drugs, bone mineral density and fracture have been mixed.

Methods: Women (n = 24) with osteopenia, assessed by broad band ultrasound attenuation, were randomized to simvastatin 20 mg, 40 mg or identical-appearing placebo for 12 weeks. Fasting lipid profiles and biochemical markers of bone formation (bone-specific alkaline phosphatase) and resorption (N-telopeptides and C-terminal propeptide of type 1 collagen) were measured at baseline, 6 and 12 weeks.

Results: Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p < 0.01 vs baseline) and 47% (p < 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively. At baseline, bone marker concentrations were similar in the three treatment groups. At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.

Conclusion: Among osteopenic women, treatment with simvastatin for 12 weeks did not affect markers of bone formation or resorption.

No MeSH data available.


Related in: MedlinePlus